Aykut Özdarendeli

1.2k total citations
50 papers, 844 citations indexed

About

Aykut Özdarendeli is a scholar working on Infectious Diseases, Ecology, Evolution, Behavior and Systematics and Animal Science and Zoology. According to data from OpenAlex, Aykut Özdarendeli has authored 50 papers receiving a total of 844 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Infectious Diseases, 9 papers in Ecology, Evolution, Behavior and Systematics and 8 papers in Animal Science and Zoology. Recurrent topics in Aykut Özdarendeli's work include Viral Infections and Vectors (14 papers), SARS-CoV-2 and COVID-19 Research (12 papers) and Vector-Borne Animal Diseases (9 papers). Aykut Özdarendeli is often cited by papers focused on Viral Infections and Vectors (14 papers), SARS-CoV-2 and COVID-19 Research (12 papers) and Vector-Borne Animal Diseases (9 papers). Aykut Özdarendeli collaborates with scholars based in Türkiye, United States and Antigua and Barbuda. Aykut Özdarendeli's co-authors include Ahmet Kalkan, Şükrü Tonbak, Münir Aktaş, Yusuf Bolat, Mehmet Özden, Engin Berber, Yasemin Bulut, Kutbeddin Demırdağ, David A. Brian and Kürşat Altay and has published in prestigious journals such as The Journal of Immunology, PLoS ONE and Journal of Virology.

In The Last Decade

Aykut Özdarendeli

49 papers receiving 795 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Aykut Özdarendeli Türkiye 19 529 216 178 113 100 50 844
Runhong Zhou China 17 1.1k 2.1× 106 0.5× 102 0.6× 160 1.4× 253 2.5× 50 1.4k
Eveline Kindler Switzerland 16 970 1.8× 116 0.5× 86 0.5× 254 2.2× 241 2.4× 18 1.4k
Arinjay Banerjee Canada 18 1.0k 1.9× 208 1.0× 137 0.8× 171 1.5× 222 2.2× 46 1.4k
Roberta M. O’Connor United States 22 628 1.2× 78 0.4× 149 0.8× 161 1.4× 189 1.9× 45 1.5k
Wun‐Ju Shieh United States 15 1.1k 2.2× 105 0.5× 461 2.6× 130 1.2× 156 1.6× 21 1.5k
Xueyong Huang China 19 825 1.6× 293 1.4× 144 0.8× 47 0.4× 473 4.7× 57 1.6k
Toni Rieger Germany 20 1.4k 2.6× 101 0.5× 298 1.7× 60 0.5× 117 1.2× 31 1.8k
L M Coffield United States 8 633 1.2× 129 0.6× 198 1.1× 16 0.1× 93 0.9× 9 946
Eun-Ha Kim South Korea 20 674 1.3× 98 0.5× 96 0.5× 71 0.6× 239 2.4× 62 1.2k
Jongyoun Yi South Korea 16 936 1.8× 365 1.7× 244 1.4× 12 0.1× 109 1.1× 54 1.3k

Countries citing papers authored by Aykut Özdarendeli

Since Specialization
Citations

This map shows the geographic impact of Aykut Özdarendeli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aykut Özdarendeli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aykut Özdarendeli more than expected).

Fields of papers citing papers by Aykut Özdarendeli

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aykut Özdarendeli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aykut Özdarendeli. The network helps show where Aykut Özdarendeli may publish in the future.

Co-authorship network of co-authors of Aykut Özdarendeli

This figure shows the co-authorship network connecting the top 25 collaborators of Aykut Özdarendeli. A scholar is included among the top collaborators of Aykut Özdarendeli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aykut Özdarendeli. Aykut Özdarendeli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Özdarendeli, Aykut. (2023). Crimean–Congo Hemorrhagic Fever Virus: Progress in Vaccine Development. Diagnostics. 13(16). 2708–2708. 11 indexed citations
3.
Tanrıöver, Mine Durusu, Özlem Altuntaş Aydın, Rahmet Güner, et al.. (2022). Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial. Vaccines. 10(11). 1865–1865. 9 indexed citations
4.
Gül, Fethi, Zeynep Burçin Gönen, Pakize Neslihan Taşlı, et al.. (2022). A pilot study for treatment of severe COVID-19 pneumonia by aerosolized formulation of convalescent human immune plasma exosomes (ChipEXO™). Frontiers in Immunology. 13. 963309–963309. 9 indexed citations
5.
Berber, Engin, et al.. (2021). Development of a protective inactivated vaccine against Crimean–Congo hemorrhagic fever infection. Heliyon. 7(10). e08161–e08161. 14 indexed citations
7.
Çelik, İ̇lhami, et al.. (2020). Isolation and characterization of severe acute respiratory syndrome coronavirus 2 in Turkey. PLoS ONE. 15(9). e0238614–e0238614. 11 indexed citations
8.
Berber, Engin, Mustafa Ertek, Şükrü Tonbak, et al.. (2013). Pseudo-plaque reduction neutralization test (PPRNT) for the measurement of neutralizing antibodies to Crimean-Congo hemorrhagic fever virus. Virology Journal. 10(1). 6–6. 17 indexed citations
9.
Özdarendeli, Aykut, Engin Berber, Kemalettin Aydın, et al.. (2009). The complete genome analysis of Crimean-Congo hemorrhagic fever virus isolated in Turkey. Virus Research. 147(2). 288–293. 41 indexed citations
10.
Saral, Yunus, Ahmet Kalkan, Aykut Özdarendeli, Yasemin Bulut, & Mehmet Ziya Doymaz. (2006). Detection of Molluscum contagiosum Virus (MCV) Subtype I as a Single Dominant Virus Subtype in Molluscum Lesions from a Turkish Population. Archives of Medical Research. 37(3). 388–391. 11 indexed citations
11.
Aksoy, Aziz & Aykut Özdarendeli. (2006). [Genotyping of hepatitis B virus by restriction enzyme analysis].. PubMed. 40(3). 215–23. 2 indexed citations
12.
13.
Kuk, Salih, et al.. (2005). Fasciola hepatica cathepsin L1 from a Turkish isolate is related to Asiatic isolates. Acta Parasitologica. 50(3). 4 indexed citations
14.
Kalkan, Ahmet, et al.. (2005). Investigation of Epstein-Barr Virus DNA in Formalin-Fixed and Paraffin- Embedded Breast Cancer Tissues. Medical Principles and Practice. 14(4). 268–271. 30 indexed citations
15.
Kalkan, Ahmet, Mehmet Özden, Turgut Yılmaz, et al.. (2004). A Case of Mumps Conjunctivitis: Detection of the Virus RNA by Nested PCR in Tear Sample. Scandinavian Journal of Infectious Diseases. 36(9). 698–700. 5 indexed citations
16.
Özdarendeli, Aykut, et al.. (2003). Polimeraz Zincir Reaksiyonu ile Transforme Bakteriyel Kolonilerın Belirlenmesi (Pzr-tarama). DergiPark (Istanbul University). 8(2). 79–82.
17.
Kuk, Salih, et al.. (2003). [Fasciola hepatica seroprevalence in the Elaziğ region].. PubMed. 36(3-4). 337–42. 23 indexed citations
18.
Kalkan, Ahmet, et al.. (2003). Seropositivity of Epstein-Barr virus in Eastern Anatolian Region of Turkey.. PubMed. 21(1). 49–53. 18 indexed citations
19.
Özdarendeli, Aykut, et al.. (2001). Serological Survey of the Infection of Parainfluenzavirus Type 3 in Cattle in Malatya. TURKISH JOURNAL OF VETERINARY AND ANIMAL SCIENCES. 25(3). 223–226. 3 indexed citations
20.
Doymaz, Mehmet Ziya, Hakan Bulut, Aykut Özdarendeli, & Yusuf Bolat. (2000). Production and Characterization of Monoclonal Anti-Ovalbumin Antibodies. TURKISH JOURNAL OF MEDICAL SCIENCES. 30(5). 411–416. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026